Evidence map›Paper›PMID 26138653›Full record

ArticleDigestive diseases and sciences2015

Durability of Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir.

Tse-Ling Fong, Andy Tien, Kahee J Jo, Danny Chu, Eddie Cheung, Edward A Mena, Quang-Quoc Phan, Andy S Yu, Wafa Mohammed, Andrew Velasco and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Digestive diseases and sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. [Generation of a novel HBeAg transgenic mice using CRISPR/Cas9 technique].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2019
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. The HBV Drugs Work: Now What?The American journal of gastroenterology · 2016
    Article
  8. 5-year efficacy of entecavir in Indian patients with chronic hepatitis B.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Tse-Ling FongAsian Pacific Liver Center, Saint Vincent Medical Center, Los Angeles, CA, USA. tselingf@usc.edu.
Andy TienAsian Pacific Liver Center, Saint Vincent Medical Center, Los Angeles, CA, USA.
Kahee J JoLiver Disease and Transplant Program, California Pacific Medical Center, San Francisco, CA, USA.
Danny ChuPrivate Practice, New York, NY, USA.
Eddie CheungDivision of Gastroenterology, University of California Davis, Davis, CA, USA.
Edward A MenaLiver Center, Huntington Research Institute, Pasadena, CA, USA.
Quang-Quoc PhanPrivate Practice, Fountain Valley, CA, USA.
Andy S YuPrivate Practice, San Jose, CA, USA.
Wafa MohammedAsian Pacific Liver Center, Saint Vincent Medical Center, Los Angeles, CA, USA.
Andrew VelascoAsian Pacific Liver Center, Saint Vincent Medical Center, Los Angeles, CA, USA.
Vinh-Huy LeDucAsian Pacific Liver Center, Saint Vincent Medical Center, Los Angeles, CA, USA.
Nickolas NguyenAsian Pacific Liver Center, Saint Vincent Medical Center, Los Angeles, CA, USA.
Steven-Bui HanDivision of Gastroenterology, Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Mimi ChangAsian Pacific Liver Center, Saint Vincent Medical Center, Los Angeles, CA, USA.
Ho S BaeAsian Pacific Liver Center, Saint Vincent Medical Center, Los Angeles, CA, USA.
Yong-Won ChoAsian Pacific Liver Center, Saint Vincent Medical Center, Los Angeles, CA, USA.
Myron J TongLiver Center, Huntington Research Institute, Pasadena, CA, USA.
Stewart L CooperLiver Disease and Transplant Program, California Pacific Medical Center, San Francisco, CA, USA.

Funding

UCSF Liver Core CenterP30DK026743 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Holger Willenbring · 1986 to 2026
$30.7M
NIDDK NIH HHS P30 DK026743
6 · The paper itself

Abstract

introductionLoss of HBeAg and development of anti-HBe (seroconversion) is seen as a milestone and endpoint in the treatment of HBeAg-positive patients with chronic hepatitis B (CHB). Among patients treated with nucleos(t)ide analogs (NA), recurrent viremia is common after discontinuation of therapy. Entecavir (ETV) and tenofovir (TDF) are highly potent NA. The durability of virological response and HBeAg seroconversion in patients treated with these agents is not well studied.

methodsWe retrospectively studied the outcomes of 54 HBeAg-positive CHB patients who were treated with either ETV (n = 30) or TDF (23) or both (n = 1) that achieved virological response and underwent seroconversion and consolidation therapy before cessation of treatment.

resultsOnly 4 (7%) patients had sustained virological, serological, and biochemical remission. Thirteen patients (24%) continued to have HBV DNA levels below 2000 IU/mL and normal alanine aminotransferase activity (ALT). Thirty-seven patients (69%) developed HBV DNA >2000 IU/mL, with 20 having elevated ALT. Among these 37 patients, 23 (62%) remained HBeAg negative/anti-HBe positive, 12 (32%) became HBeAg positive, and 2 (5%) were HBeAg and anti-HBe negative. Duration of consolidation therapy did not correlate with low versus high level of virological relapse.

conclusionsDurability of HBeAg seroconversion associated with ETV or TDF was not superior to that reported in patients treated with less potent NA. Our results, aggregated with others, suggest HBeAg seroconversion should not be considered as a treatment endpoint for most HBeAg-positive patients treated with NA. Future updates of treatment guidelines should reconsider HBeAg seroconversion as an endpoint to therapy.

Indexed as

AdultAgedAged, 80 and overAntiviral AgentsBiomarkersDNA, ViralFemaleGuanineHepatitis B, ChronicHepatitis B e AntigensHepatitis B virusHumansKaplan-Meier EstimateMaleMiddle AgedRecurrenceAntiviral AgentsBiomarkersDNA, ViralentecavirGuanineHepatitis B e AntigensTenofovirRelapseRemissionSeroreversion

Identifiers

PMID26138653
PMCPMC4803449

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.